BLRX has been the topic of several other reports. Zacks Investment Research raised shares of BioLineRx from a hold rating to a buy rating and set a $1.00 price target on the stock in a report on Friday, April 21st. HC Wainwright set a $4.00 price target on shares of BioLineRx and gave the stock a buy rating in a report on Tuesday, April 18th. Oppenheimer Holdings, Inc. started coverage on shares of BioLineRx in a report on Friday, August 4th. They issued an outperform rating and a $3.00 price target on the stock. Roth Capital started coverage on shares of BioLineRx in a report on Thursday, August 3rd. They set a buy rating and a $3.00 price objective on the stock. Finally, ValuEngine raised shares of BioLineRx from a sell rating to a hold rating in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. BioLineRx currently has a consensus rating of Buy and a consensus price target of $2.59.
BioLineRx (NASDAQ:BLRX) remained flat at $1.13 during mid-day trading on Tuesday. The company had a trading volume of 337,720 shares. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42. The company’s market cap is $108.05 million. The company’s 50-day moving average is $1.00 and its 200 day moving average is $0.98.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, analysts expect that BioLineRx will post ($0.24) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in BioLineRx during the first quarter worth about $3,018,000. KCG Holdings Inc. increased its position in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares in the last quarter. Renaissance Technologies LLC acquired a new position in BioLineRx during the first quarter worth about $126,000. Benchmark Capital Advisors increased its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. Finally, Citadel Advisors LLC increased its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Institutional investors own 34.98% of the company’s stock.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.